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ABSTRACT
Human telomerase reverse transcriptase (hTERT) plays
a central role in telomere lengthening for continuous cell
proliferation, but it remains unclear how extracellular
cues regulate telomerase lengthening of telomeres.
Here we report that the cytokine bone morphogenetic
protein-7 (BMP7) induces the hTERT gene repression in
a BMPRII receptor- and Smad3-dependent manner in
human breast cancer cells. Chonic exposure of human
breast cancer cells to BMP7 results in short telomeres,
cell senescence and apoptosis. Mutation of the BMPRII
receptor, but not TGFbRII, ACTRIIA or ACTRIIB receptor,
inhibits BMP7-induced repression of the hTERT gene
promoter activity, leading to increased telomerase
activity, lengthened telomeres and continued cell pro-
liferation. Expression of hTERT prevents BMP7-induced
breast cancer cell senescence and apoptosis. Thus, our
data suggest that BMP7 induces breast cancer cell
aging by a mechanism involving BMPRII receptor- and
Smad3-mediated repression of the hTERT gene.
KEYWORDS BMPRII, TGFbeta, hTERT, telomerase,
telomeres, senescence, breast cancer cells
INTRODUCTION
Human telomerase reverse transcriptase (hTERT) is the
catalytic subunit of telomerase required for telomere main-
tenance and continuous cell proliferation in most cancers (de
Lange, 2002; Blasco, 2005; Blackburn et al., 2006; Shay and
Wright, 2006). The availability of hTERT, however, is under a
strict regulation at the gene transcription level (Kyo and
Inoue, 2002; Takakura et al., 2005). A number of cellular
factors have been implicated as playing signiﬁcant roles in
regulating hTERT gene expression, among which are the
proto-oncogene Sp1/Sp3, c-myc, Ets2 transcription factor
(Wu et al., 1999; Kyo et al., 2000; Xu et al., 2008; Horn et al.,
2013; Huang et al., 2013; Borah et al., 2015; Cheng et al.,
2015), and the Smad3 repressor (Hu et al., 2006; Li et al.,
2006). Since the hTERT gene is repressed during cell dif-
ferentiation (Bestilny et al., 1996; Holt et al., 1996; Parsch
et al., 2004; Li et al., 2005), extracellular factors that regulate
cell differentiation may be involved in programming hTERT
gene expression and thereby telomerase-mediated mainte-
nance of telomere homeostasis (Li et al., 2005, 2006; Li and
Liu, 2007). We and others show that TGF-β is involved in
cancer cell proliferation under certain conditions (James
et al., 2005; Li et al., 2005, 2006; Biswas et al., 2007; Gal-
liher and Schiemann, 2007), suggesting that extracellular
cytokines regulate the hTERT gene.
Bone morphogenetic proteins (BMPs) operate though
autocrine and paracrine mechanisms to regulate cell prolif-
eration, differentiation and apoptosis during development
(Patel and Dressler, 2005; Varga and Wrana, 2005). BMPs
act on their cell membrane type I and II receptors of serine/
theonine kinases (Hogan, 1996; Shi and Massague, 2003;
Varga and Wrana, 2005) and induce phosphorylation and
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nuclear signaling of Smad1, Smad5 and Smad8 proteins
(Attisano and Wrana, 2002; Massague et al., 2005; Varga
and Wrana, 2005). Bone morphogenetic protein-7 (BMP7;
osteogenic protein-1) is a potent inducer of cell differentiation
required for vertebrate development. However, the function
of BMP7 in adult tissues remains to be fully explored (Ho-
gan, 1996; Wang and Hirschberg, 2004a; Patel and Dress-
ler, 2005; Buijs et al., 2007b; Sugimoto et al., 2007; Zeisberg
et al., 2007). BMP7 maintains the phenotypes of epithelium
and endothelium against mesenchymal transition (Buijs
et al., 2007b; Zeisberg et al., 2007). BMP7 is also readily
detectable in solid tumors including breast and prostate
carcinomas, and involved in regulating tumor cell prolifera-
tion and transition (Miyazaki et al., 2004; Yang et al., 2005;
Alarmo et al., 2006, 2007; Buijs et al., 2007b; Notting et al.,
2007; Rothhammer et al., 2007; Zeisberg et al., 2007).
Previous studies show that BMP7 induces Smad5 signaling
to antagonize TGF-β-induced Smad3 nuclear accumulation
and block the transcriptional up-regulation of the Smad3
target CAGA box promoter activity in mesangial cells (Wang
and Hirschberg, 2004b), but in breast cancer cells, BMP7
appears inhibiting TGF-β-induced Smad3 target CAGA box
promoter activity (Buijs et al., 2007a).
In the present study, we found that telomerase activity in
human breast cancer cells is inhibited by BMPRII receptor-
mediated signaling. Treatments of the cells in cultures with
BMP7 in every two-day for two weeks lead to telomere
shortening and cell senescence. Forced gene expression of
hTERT inhibits BMP7-induced breast cancer cell senes-
cence and death. In addition to stimulating Smad1, Smad5
and Smad8 phosphorylation and nuclear translocation,
BMP7 also induces Smad3 phosphorylation and nuclear
accumulation in breast cancer cells and silencing Smad3
abrogates BMP7-induced telomerase inhibition. Thus, we
show that BMP7 inhibits telomere maintenance by a
mechanism involving BMPRII receptor and Smad3 signal-
ing to suppress hTERT gene expression in breast cancer
cells.
RESULTS
BMP7 induces telomerase inhibition and telomere
shortening in cultured breast cancer cells
To investigate a potential involvement of the BMP family in
telomerase activity, we examined the effects of BMP2,
BMP4, BMP5, BMP6 and BMP7 on telomerase activity by
spiking the medium of cultured human breast cancer MCF-7
cells with puriﬁed recombinant human cytokines. Incubation
of MCF-7 cells with different concentrations of BMP7 for 48 h
resulted in more than 70% inhibition of telomerase activity
(Fig. 1A). The median inhibitory concentration (IC50) of
BMP7 was 4 ± 0.5 ng/mL and maximal inhibitory concen-
tration was 20 ± 0.8 ng/mL (n = 3) (Fig. 1A), concentrations
that are within the levels of BMPs administered and
observed in vivo (Simic et al., 2006; Ma et al., 2007).
In contrast to BMP7, incubations of the cells with BMP2,
BMP4, BMP5 or BMP6 showed no signiﬁcant inhibitory effect
on the telomerase activity (Fig. 1A). Consistent with a speciﬁc
effect, BMP7 antibodies abrogated the inhibition, and dena-
tured BMP7 had no effect (Fig. 1B). BMP7 also elicited
telomerase inhibition in a time-dependent manner (Fig. 1A),
with the inhibition occurring in about 24 h and lasted for 2–
3 days. In addition to inhibiting telomerase activity, BMP7
consistently induced a signiﬁcant reduction in the size of
telomeres. Pulsatile treatments of cultured MCF-7 cells with
BMP7 (30 ng/mL) for 15 h thee times a week over two weeks
resulted in signiﬁcantly shortened telomeres (Fig. 1C and
1D), as revealed by quantitative ﬂuorescence in situ
hybridization (Q-FISH) using a speciﬁc telomeric DNA probe
in the metaphase cell spread preparations. As shown in
Fig. 1C, BMP7 treatments induced a marked shift of the peak
of the telomere ﬂuorescence intensity signals between the
control and BMP7-treated groups. While the majority of the
telomere sizes were distributed with high frequency at the 6–
26 ﬂuorescence units (peaking at 11) in the control cells, the
peak of telomere signals was at the 6th ﬂuorescence unit in
the BMP7-treated group exhibiting much shorter telomeres
than that in the control group. Comparison of the two telom-
ere ﬂuorescence distribution peaks showed P value to be
less than 0.0001, by Kolmogorov-Smirnov test. On average,
the telomeres in the BMP7-treated group were 25%–30%
Figure 1. BMP7 induces inhibition of telomerase
activity and shortening of telomeres in cultured breast
cancer cells. (A) BMP7 induces a concentration- and
time-dependent inhibition of telomerase activity in cultured
human breast cancer MCF-7 cells. Cells were incubated
with different concentrations of BMPs as indicated for 48 h
(solid lines), or with BMP7 (10 ng/mL) for different periods
of time as indicated (dot line). Telomerase activity was
determined by measuring newly synthesized telomeric
DNA and quantitated by densitometry. The results are
presented in mean ± SD from thee determinations.
(B) Effects of BMP7 antibodies or heating denatured
BMP7 on telomerase activity. BMP7 with or without
heating at 80 °C for 2 min was incubated in the presence
or absence of BMP7 antibodies (1:100 dilution) in cultured
cells. Positive control is 1 in 10 dilution of MCF7 cell
nuclear telomerase extracts and negative control is the
Tris buffer used for telomerase extraction. Telomere DNA
produced and internal control are indicated. (C) Effect of
BMP7 on telomere length in MCF-7 cells. Cells were
treated with or without BMP7 (30 ng/mL) for 15 h followed
by replacement with fresh medium on every second day
for two weeks. Telomeres were determined by Q-FISH and
the distributions of telomere length are presented by
ﬂuorescence intensity versus frequencies. (D) Illustrative
micrographs of ﬂuorescence-labeled telomeres in meta-
phase spreads. (E) Histograms of mean telomere ﬂuores-
cence intensities (± S.E.M.) in control and BMP7-treated
cells.
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shorter than the telomeres in the normal control cells (Fig. 1D
and 1E). Thus, the data together clearly showed that BMP7
induced inhibition of telomerase activity and shortening of
telomeres in cultured human breast cancer cells.
BMP7 induces breast cancer cell senescence and death
by a mechanism dependent on telomerase inhibition
With the possible mechanisms of BMP7 action on the cell
surface to regulate gene expression programs and cellular
phenotypes, we treated cultured breast cancer cells with
BMP7 overnight with repeats in every two-day for two weeks
and examined cell senescence and death. In the BMP7
treated cell cultures, we observed the cells characteristics of
enlarged and ﬂattened cell morphology, greater cytoplasm/
nuclear ratio, and expressions of cell senescence markers
such as β-galactosidase and p16 (Janzen et al., 2006;
Molofsky et al., 2006). As shown in Fig. 2A, treatment of
MCF-7 cells with BMP7 (30 ng/mL, 15 h in every two-day for



















































































































Figure 2. BMP7 induces cancer cell senescence. (A) BMP7 induces an increase in cancer cell senescence. MCF-7 cells were
incubated with or without BMP7 (30 ng/mL) for 15 h three times a week for two weeks. Senescence-like cells were counted in multiple
micrographs and presented as means with comparison between the control and BMP7-treated groups. The results are in mean ± SD
from ﬁve determinations. (B) Representative micrographs of cultured MCF-7 cells photographed under phase contrast microscope at
10X magniﬁcation. Senescence-like cells are indicated by arrows. (C) Inhibition of telomerase activity in MCF-7 cell cultures treated
with BMP7 for 15 h three times a week for two weeks. The result was from one of two assays. (D) Increases in p16, p53 and p21 in the
MCF-7 cells treated with BMP7 (10 ng/mL) for different periods of time, determined by Western blotting. The data presented in top
panel were from one of two similar experiments, and the data in bottom panel are means of two determinations.
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Figure 3. BMP7-induced breast cancer cell senescence is dependent on hTERT gene repression. (A) β-galactosidase activity
determined by β-Gal staining in cultured MCF-7 cells treated with BMP7 (10 ng/mL) for different periods of time. Results were from
phase contrast microscopy at 20X magniﬁcation. Arrowed are enlarged β-galactosidase positive senescent cells. (B) Up- and down-
regulation of telomerase activity by GFP-hTERT and GFP-hTERT shRNA. MCF-7 cells were transfected for 24 h. Total cell lysates
were subjected to telomerase activity assay. De novo synthesized telomeric DNA reﬂecting telomerase activity and internal loading
control are indicated. (C) Over- and under-expression of hTERT by gene transfection. MCF-7 cells transfected with GFP, GFP-hTERT
or GFP-hTERT shRNA were extracted for mRNA. RT-PCR was performed to verify hTERT gene expression with actin as control.
(D) Effects of hTERT over- and under-expression on BMP7-induced breast cancer cell senescence. MCF-7 cells expressing basal,
increased or decreased levels of hTERT were examined for cell senescence by β-Gal staining. Positive cells with blue staining are
indicated by arrows. (E) Quantiﬁcation of β-Gal positive cells in time course studies. Results are mean plus standard errors (n = 3)
Asterisk denotes p value less than 0.001 when compared with controls.
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cell senescence (Fig. 2A). The increase in cell senescence
in the BMP7-treated cultures was associated with reduced
cell numbers (Fig. 2B) and protein concentrations (not
shown), decreased telomerase activity (Fig. 2C). The inhi-
bition of telomerase activity in these cells was by 60%–70%.
Consistent with cell senescence, BMP7-treated cell cultures
showed increased p53, p21 and p16 (Fig. 2D). The levels of
p16, p53 and p21 were 2–5 folds of controls plateaued in
24 h of BMP7 treatment (Fig. 2D). Thus, our data showed
that prolonged exposure to BMP7 induced tumor cell growth
arrest, senescence and death.
To further determine BMP7-induced breast cancer cell
senescence and the role of telomerase inhibition, β-Gal
staining was carried for the β-galactosidase activity in MCF-7
cells treated with BMP7 for different periods of time. As
shown in Fig. 3A, β-Gal positivity was observed in the
enlarged cells (arrowed) in MCF-7 cell cultures that were
treated with BMP7 in 72 h or 96 h, conﬁrming that BMP7
treatment is associated with breast cancer cell senescence.
To investigate if telomerase inhibition induced by BMP7
mediated BMP7-induced cancer cell senescence, we carried
out over- and under-expression of hTERT with GFP-hTERT
and GFP-hTERT shRNA gene expression systems respec-
tively, using GFP alone as control. In 24 h of transfection,
transfected cells were sorted to purify the different transfor-
mants by ﬂuorescence activated cell sorter (FACS). Telom-
erase activity (Fig. 3B) and hTERT mRNA (Fig. 3C) was
determined to verify the changes of different levels of
telomerase and hTERT gene expression by TRAP and RT-
PCR respectively. Signiﬁcantly, treatment of the GFP, GFP-
hTERT and GFP-hTERT shRNA transfected cells with or
without BMP7 resulted in different patterns of β-Gal staining.
As shown in Fig. 3D and 3E, BMP7 (30 ng/mL) induced cell
senescence in GFP transfected cells, and similarly, hTERT
shRNA also induced cell senescence without BMP7 treat-
ment. However, expression of recombinant hTERT pre-
vented BMP7-induced senescence and hTERT shRNA
increased BMP7-induced senescence (Fig. 3D and 3E).
Comparison of BMP7 alone or hTERT shRNA alone with
BMP7 plus hTERT shRNA showed a signiﬁcant difference
between BMP7 alone and BMP7 plus hTERT shRNA
(7.7 ± 0.55 versus 10.5 ± 0.82, P < 0.01), or between hTERT
shRNA alone and hTERT shRNA plus BMP7 (8.7 ± 0.62
versus 10.5 ± 0.82, P < 0.03). These ﬁndings that BMP7 plus
hTERT shRNA induced cell senescence to a greater degree
than that by BMP7 or hTERT shRNA alone suggest that
hTERT suppression is involved but not the only factor in
mediating BMP7-induced cell senescence.
To explore BMP7 instigation of breast cancer cell apop-
totic cell death, we stained the BMP7 treated cells with
annexin V and propidium iodide (PI), and analyzed double
positive cells in FACS. Incubation of MCF-7 cells with BMP7
(30 ng/mL) for 24 h resulted in a signiﬁcant increase in the
percentage of annexin V- and PI-positive cells (Fig. 4A). The
number of apoptotic cells in 24 h of BMP7-treated cell cul-
tures was doubled when compared to the basal levels in
control group. To examine the involvement of telomerase
inhibition in breast cancer cell apoptosis, we observed an
increased response of apoptosis to the transient overex-
pression of Smad3 that is an hTERT gene repressor or to the
transient expression of the hTERT shRNA to silence the
hTERT gene. The levels of induced apoptosis by BMP7
treatment, Smad3 overexpression or hTERT shRNA were
within 10%–20% of total cells (Fig. 4A), consistent with a
speciﬁcally increased incidence of apoptosis due to telom-
erase inhibition.
To further attest the role of hTERT in the BMP7-induced
cell death, we similarly transfected MCF-7 cells with
recombinant GFP-hTERT, GFP-hTERT shRNA or GFP only
gene expression plasmids, isolated the GFP-positive trans-
formants by FACS, and treated the cells with BMP7 (10 ng/
mL) for 24 h (Fig. 4B and 4C). In the homogenously trans-
fected cell cultures, we found that BMP7 treatment doubled
the number of apoptotic cells of control, and hTERT shRNA
induced a signiﬁcant cell death in parallel (Fig. 4B). In
addition, hTERT shRNA did not potentiate the levels of cell
death induced by BMP7 (Fig. 4B), suggesting a possibly
shared mechanism. Overexpression of hTERT wild type
signiﬁcantly reduced the levels of BMP7-induced cell death
(Fig. 4B). In average, the gene expression GFP-hTERT
reduced the levels of cell death induced by BMP7 from 19%
to 14% (P = 0.007) (Fig. 4C). These data demonstrated that
hTERT repression mediated the breast cancer cell apoptosis
induced by BMP7 at least in part. Furthermore, we also
noted that hTERT did not completely prevent BMP7-induced
cells. As shown in Fig. 4C, although hTERT overexpression
reduced BMP7-induced cell death signiﬁcantly, BMP7 treat-
ment of GFP-hTERT transformants still showed more cell
death than the GFP-hTERT transformants without BMP7
treatment (P = 0.001) (Fig. 4C). Consistently, while hTERT
shRNA induced a signiﬁcant increase in apoptosis
(P = 0.004), the cell death induced by the combination of
hTERT shRNA and BMP7 was greater than hTERT shRNA
alone (P = 0.002) (Fig. 4C). Thus, over and above hTERT
repression, other mechanism(s) may exist to participate in
Figure 4. BMP7 induces hTERT-dependent breast cancer
cell apoptosis. (A) BMP7 induces breast cancer cell apoptosis.
MCF-7 cells were treated with BMP7 (10 ng/mL), or transfected
with Smad3 or hTERT shRNA expression plasmids for 48 h.
Cells were stained with Annexin V and propidium iodide (PI),
and analyzed by FACS. (B) Effects of over- and under-
expression of hTERT on BMP7-induced breast cancer MCF-7
cell death. Cells were transfected with pEGFP, pEGFP-hTERT
or pEGFP-hTERT shRNA for 24 h, followed by FACS sorting.
GFP-positive cells were cultured for 15 h before being treated
with BMP7 (10 ng/mL, 24 h) and analysed by apoptotic cell
staining in FACS. (C) Comparison and statistical analysis of the
mean inhibitory effect of recombinant hTERTon BMP7-induced
cell death. The data are mean ± SD from eight similar
experiments. P values were from student t-tests.
b
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mediating BMP7-induced breast cancer cell senescence as
well as apoptosis.
BMP7 repression of the hTERT gene is mediated
by Smad3 signaling
To investigate the mechanisms of the inhibitory effect of
BMP7 on telomerase activity, we determined hTERT gene
expression as a possible function of the activation of Smad
proteins. BMP7 stimulated the phosphorylation and nuclear
retention of Smad1/5/8 complex, similar to that by BMP2,
BMP4 and BMP5 (Fig. 5A). In a preliminary experiment, we
observed no apparent effect of Smad1, Smad5 and Smad8
on telomerase inhibition (not shown). However, we found
surprisingly that Smad3 responded to BMP7. As shown in
Fig. 5B, incubation of cultured MCF-7 cells with BMP7 for
different periods of time from 10 min to 2 h resulted in Smad3
phosphorylation. The phosphorylation was gradually
increased and the maximal levels of phosphorylation were
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Figure 5. BMP7 induces Smad3 phosphorylation, nuclear translocation and gene transcriptional activity. (A) Smad1/5/8
phosphorylation and nuclear accumulation stimulated by BMP7, BMP2, BMP4 and BMP5. MCF-7 cells were incubated with the
cytokines (30 ng/mL) for different time periods as indicated. Cells were fractionated by differential centrifugation for the cytoplasmic
and nuclear fractions. Phosphorylation of Smad1/5/8 complex in response to the different cytokines as indicated was examined by
Western blotting using speciﬁc anti-phosphorylated Smad1/5/8 antibodies. (B) Smad3 phosphorylation and nuclear accumulation
stimulated by BMP7 and TGF-β. MCF-7 cells were incubated with BMP7 or TGF-β (30 ng/mL) for 10, 30, 60 and 120 min. Cells were
fractionated and Smad3 phosphorylation was determined Western blotting using speciﬁc anti-phosphorylated Smad3 antibody.
Protein loading controls in each fraction were monitored by Western blotting using anti-actin antibodies. Data were representatives of
at least thee similar experiments. (C) Immunoﬂuorescence staining of phosphor-Smad3 in BMP7-treated MCF-7 cells at different time
points. Cells were treated with BMP7 for different periods of time as indicated. Micrographs of immunoﬂuorescence staining using
speciﬁc antibody against phosphor-Smad3 and staining for the nuclei are shown. (D) BMP7 activation of Smad3 inducible (CAGA)12
Luc promoter. Cells transfected with pCAGA12 Luc were treated with different cytokines as indicated at the concentrations of 10 ng/
mL for 24 h. Luciferase activity was determined as described in MATERIALS AND METHODS. Data are mean ± SD from four
determinations.
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dependent manner (Fig. 5B). In addition, the phosphorylation
of Smad3 occurred in association with the phosphorylated
protein nuclear accumulation from ten min of BMP7 treat-
ment, which lasted for two h of observation (Fig. 5B). As
controls, Smad3 phosphorylation was also induced by TGF-
β stimulation (Fig. 5B), but no Smad3 phosphorylation was
observed in the cells treated with BMP2, BMP4 or BMP5 (not
shown). Immunoﬂuorescence staining of phosphor-Smad3
intracellular distribution conﬁrmed the data obtained by cel-
lular fractionation. As shown in Fig. 5C, predominant cyto-
plasmic staining of phospho-Smad3 was observed in non-
treated MCF-7 cells, whereas predominant nuclear staining
of phosphor-Smad3 was observed in some cells 10 min after
BMP7 treatment and in most cells 30 or 60 min after the
BMP7 treatment.
To further determine the increased Smad3 activity in
response to BMP7 stimulation, we measured Smad3 gene
transcriptional activity using a Smad3 responsive luciferase
gene reporter assay in MCF-7 cells treated with or without
BMP7. MCF-7 cells were transfected with Smad3-responsive
gene promoter (pGL3-(CAGA)12-Luc luciferase reporter
(Dennler et al., 1998)) for 24 h, and the transfected cells were
further treated with 30 ng/mL of BMP7, TGF-β, BMP2, BMP4,
BMP5 or BMP6 for 48 h. As shown in Fig. 5D, BMP7 or TGF-β
induced marked increases in the luciferase reporter gene
activity that is under the transcriptional control of the Smad3-
speciﬁc promoter. The increased luciferase activity induced
by BMP7was four-ﬁve folds of control, which was comparable
to that induced by TGF-β (Fig. 5D). In contrast, BMP2, BMP4,
BMP5 or BMP6 did not elicit any signiﬁcant increase in the
luciferase activity driven by Smad3 responsive promoter
(Fig. 5D). These data further conﬁrmed that BMP7 triggered
the nuclear signaling of Smad3 in breast cancer cells.
With the observed correlative changes of Smad3 nuclear
signaling (Fig. 5B, 5C and 5D) and telomerase inhibition




















































































Figure 6. BMP7 induced inhibition of the hTERT gene expression and telomerase activity requires Smad3. (A) Effects of
silencing Smad3 and c-myc on BMP7-induced repression of hTERT mRNA. MCF-7 cells were transfected with (lanes 2–6) or without
(lane 1) different customer synthesized small interference RNA (siRNA) as indicated for 48 h. Cells were then treated with (lanes 4–6)
or without (lanes 1–3) BMP7 (10 ng/mL) for 24 h. Gene expressions of hTERT, Smad3, c-myc and actin were determined by
measuring their respective mRNA by RT-PCR using speciﬁc primers. (B) Quantiﬁcation of telomerase activity from breast cancer cells
treated with BMP7 plus or minus the gene silencing of Smad3. Telomerase activity was measured by TRAP and the levels of
telomerase activity were quantitated by scanning of the autoradiographs with densitometry. Data are mean plus standard errors
(n = 3) and asterisk notes P < 0.001 compared with non-treated control. (C) Effects of silencing Smad3 and c-myc on BMP7-induced
inhibition of telomerase activity. MCF-7 cells were transfected with siRNA speciﬁc to Smad3 (lanes 7–10) or c-myc mRNA (lanes 11–
14) for 48 h. Cells were then treated with BMP7 (10 ng/mL) (lanes 5–8, 11–12) or diluent (lanes 1–4, 9–10, 13–14) for 24 h. Lanes 1
and 2 were controls: lane 1 was a positive control of telomerase extracts and lane 2 was a negative control treated with RNase A.
These data presented were representative of one of at least three similar experiments.
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role of the BMP7-induced Smad3 signaling in mediating the
BMP7-induced hTERT gene repression by silencing the
Smad3 gene and then determining if the inhibitory effect of
BMP7 on the hTERT gene expression is mitigated. As
shown in Fig. 6, silencing Smad3 gene expression resulted
in increased gene expressions of c-myc and hTERT (Fig. 6A,
lane 2 or 4, versus lane 1), and increased telomerase activity
(Fig. 6B, lane 9–10 versus lane 3–4). In contrast, silencing
c-myc gene expression resulted in inhibition of the hTERT
gene expression (Fig. 6A, lane 3 or 5, versus lane 1), or
telomerase activity (Fig. 6B, lane 11–14 versus lane 3–4),
consistent with previous ﬁndings that Smad3 is a repressor
and c-myc is a transcription factor of the hTERT gene
respectively (Wu et al., 1999; Kyo and Inoue, 2002; Takakura
et al., 2005; Li et al., 2006). However, silencing Smad3
markedly relaxed the BMP7 inhibition of the hTERT gene
expression and telomerase activity (lane 4 versus lane 6 of
Fig. 6A, and lanes 7–8 versus lanes 5–6 of Fig. 6B). These
ﬁndings that knocking down Smad3 gene expression dis-
rupted BMP7-induced telomerase inhibition clearly sug-
gested that Smad3 was required in BMP7-induced
telomerase inhibition in human breast cancer cells. Thus,
BMP7 employed Smad3 to repress the hTERT gene, inhibit
telomerase activity and induce telomere shortening in cul-
tured breast cancer cells.
Roles of TGF-β family cytokine receptors in regulating
the hTERT gene, telomerase activity and telomere
length
BMP7 has been shown to bind BMPRII or ACTRIIB
receptors to induce intracellular signaling (Shi and Mas-
sague, 2003). To establish a speciﬁcally receptor-mediated
effect of BMP7 on telomerase inhibition, we performed
dominant negative gene expression by truncating the cyto-
plasmic domains of all four TGF-β family cytokine receptors,
BMPRII, TGFβRII, ACTRIIA and ACTRIIB. We determined
the effects of forced expression of these receptor truncation
mutants on hTERT gene promoter activity, telomerase
activity and telomere length. Recombinant TGFβRII,
BMPRII (Fig. 7A), ACTRIIA and ACTRIIB (not shown)
receptors with missing intracellular domains were all
expressed on the MCF-7 breast cancer cell surface as
expected. Examination of their effects on hTERT gene
promoter activity following transient gene expressions of
these receptor mutants showed distinct patterns. Mutation
of BMPRII receptor resulted in a signiﬁcant elevation (20%–
30%, P < 0.01) of the basal hTERT gene promoter activity
compared with the controls expressing GFP only in MCF-7
breast cancer cells (Fig. 7B), suggesting that BMPRII
receptor mediates an endogenous inhibitory signal to the
repression of the hTERT gene promoter activity in breast
cancer cells. Treatment of the different receptor mutants
with BMP7 resulted in a consistent repression of the hTERT
gene promoter activity compared with BMP7-untreated
controls (∼40%, P < 0.01) (Fig. 7B). Mutation of BMPRII
receptor blocked the inhibitory effect of BMP7, whereas
mutation of TGFβRII or ACTRIIA receptors did not affect
BMP7 inhibition of the hTERT gene promoter (Fig. 7B),
suggesting that BMPRII receptor, but not TGFβRII or
ACTRIIA receptors, mediates the inhibition of the hTERT
gene induced by BMP7. In addition, mutation of ACTRIIB
receptor also inhibited BMP7-induced repression of the
hTERT gene promoter activity albeit to a signiﬁcantly less
extent than that induced by BMPRII receptor mutation
(Fig. 7B), suggesting that ACTRII receptor plays a less
dominant role than that played by BMPRII receptor in
mediating BMP7-induced hTERT gene repression.
To investigate the effects of TGF-β family cytokine
receptor mutations on endogenous telomerase activity and
telomere length in breast cancer cells, we established
stable gene expressions of the receptor mutants along with
Figure 7. Truncation of BMPRII receptor blocks BMP7-
induced repression of the hTERT gene and induces
increased telomerase activity and telomere length in breast
cancer cells. (A) Schematic presentation of wild type TGF-β
receptor and recombinant truncated GFP fusion receptors.
(B) Expression of truncated TGF-β or BMP type II receptors in
MCF-7 breast cancer cells. Cells were transiently transfected
with CFP control, CFP-BMPRII 1–172 or GFP-TGFβRII 1–214
for 24 h before the cells were ﬁxed and observed by confocal
microscopy. (C) Effects of mutations of TGF-β family receptors
on the hTERT gene promoter activity. MCF-7 (hatched bars)
and PMC42 (white bars) breast cancer cells were co-trans-
fected for 24 h with hTERT gene promoter p330 upstream of a
luciferase reporter gene together with GFP, GFP-TGF-β RII 1–
214, GFP BMPRII 1–172, GFPACTRIIA 1–161 or GFPACTRIIB
1–160 for 24 h. Cells were treated with or without BMP7 (10 ng/
mL, 4 h) followed by luciferase activity assay as described in
Materials and Methods. Data are mean ± SD from three
experiments determined in triplicate. a, P < 0.01 compared with
GFP only control; b, P < 0.01 compared with corresponding
gene transfection without BMP7 treatment; c, P < 0.01 com-
pared with GFP control treated with BMP7; and d, P < 0.01
compared with BMPRII mutation treated with BMP7. (D) Effects
of truncated TGF-β family receptors on telomerase activity.
MCF-7 cells were stably transfected with various gene expres-
sion plasmids as indicated and the transfected cells were
selected in cultures for approximately 70 days. GFP-positive
cells sorted by FACS were examined for telomerase activity as
described in Materials and Methods. Telomeric DNA and
internal control are indicated by arrows. (E) Effects of truncated
TGF-β family receptors on telomere length. Cells with stable ex-
pression of TGF-β family cytokine receptor truncation mutants
for ∼70 days in cultures were analyzed for telomere length as
described MATERIALS AND METHODS. The average sizes of
telomere repeat fragment (TRF) under different gene expres-
sion conditions are indicated on the right of the autoradiograph
with lane numbers. Data were representatives of multiple
measurements from 2–3 experiments.
b
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negative and positive controls by repeated antibiotic selec-
tion and FACS sorting for GFP-positive cells. Stable ex-
pression of the truncated TGF-β family cytokine RII
receptors for ∼2.5 months resulted in a signiﬁcantly
increased telomerase activity (Fig. 7C), comparable to a
positive control induced by overexpression of the Ets Id (Xu
et al., 2008). In contrast, expressions of TGF-βRII, ACTRIIA
or ACTRIIB all resulted in decreased telomerase activity
compared with GFP only control (Fig. 7C). Measurement of
telomere repeat fragments (TRF) in the breast cancer cell
lines stably expression TGF-β family cytokine receptor
mutants showed consistent results. As shown in Fig. 7D,
cells with dominant negative BMPRII exhibited lengthened
TRF compared with that in cells expressing GFP only (4.8 kb
vs. 4.0 kb). Conversely, cells expressing dominant negative
TGFβRII or AVTRII receptors showed decreased TRFs
(Fig. 7D). These stimulatory effects of BMPRII and ACTRIIB
mutation were consistent with the results obtained from
transient gene expression experiments in the absence of
BMP7 suggesting that wild type BMPRII as well as ACTRIIB
receptors were involved in mediating a negative regulation of
telomerase activity. In contrast, the inhibitory effects of
TGFbRII and ACTRIIA mutations were only observed in the
cells stably expressing the receptor mutants, suggesting a
possibly involvement of other unidentiﬁed mechanisms that
require further investigation.
To investigate whether or not the observed telomerase
inhibition induced by BMP7, mediated by BMPRII receptor, is
limited to the MCF-7 breast cancer cell line, we exploited
another breast cancer cell line—PMC42 cells. Treatment of
PMC42 cells with BMP7 resulted in a signiﬁcant repression
of the hTERT gene promoter. The extent of BMP7-induced
hTERT gene promoter inhibition was similar to that induced
by BMP7 in MCF-7 cells (Fig. 7B). Overexpression of BMP
RII receptor similarly blocked BMP7-induced hTERT gene
repression in PMC42 breast cancer cells (Fig. 7B). These
data suggested that BMP7 negatively regulated telomerase
activity though the BMPRII receptor in more than one breast
cancer cell line. Together, these experiments demonstrated
that BMPRII and to a less degree ACTRIIB receptors
mediated BMP7-induced hTERT gene repression, inhibition
of telomerase activity and shortening of telomeres in breast
cancer cells.
DISCUSSION
Consistent with the notion that telomerase is subject to
membrane receptor-mediated extracellular micro-environ-
mental regulation (Ogawa et al., 2006; DamLe et al., 2012;
Jacob et al., 2016), in this study, we demonstrate that
BMPRII receptor is involved in mediating recombinant
human BMP7 inhibition of telomerase activity and telomere
maintenance in cultured human breast cancer cells, resulting
in cancer cell senescence and death. Our data demonstrate
that telomerase maintenance of telomeres in tumor cells is
subject to regulation by extracellular cytokine and that the
BMP7 pathway plays a signiﬁcant role in the negative reg-
ulation of telomerase activity and telomere maintenance in
cancer. The maintenance of telomeres by telomerase in
cancer is therefore likely to be reprogrammable by a deﬁned
extracellular environment, probably by a combination of
extracellular factors with BMP7 to be an inhibitory cytokine of
telomerase-mediated telomere homeostasis.
The BMP7-induced occurrence of breast cancer cell
senescence appears several days after treatment, following
the inhibition of telomerase activity. Pulsatile treatments of
breast cancer cells with BMP7 for two weeks are effective to
induce a signiﬁcant shortening of telomeres, marked
increase in cell senescence and drastic loss of cultured cells.
Consistently, BMP7 administration and telomerase inhibition
are associated with precipitated increases of the cell cycle
checkpoint protein p16 and tumor suppressor protein p53.
Critical in tumor cell ageing and death (Krimpenfort et al.,
2007; Xue et al., 2007), increased p16 and p53 activities are
involved in telomere crisis responses coupling telomere
deregulation with cell senescence and death (Smo-
gorzewska and de Lange, 2002; Jacobs and de Lange,
2005). Thus, BMP7 may induce cancer cell ageing and
death with a series of molecular and cellular events including
telomerase inhibition, telomere shortening, and telomere-
associated DNA damage response (Artandi et al., 2000; de
Lange, 2002; Denchi and de Lange, 2007).
Our ﬁnding of BMP7-induced breast cancer cell apoptosis
is consistent with previous ﬁndings that BMP7 induces the
program cell death of myeloma cells (Ro et al., 2004) and
prostate cancer cells (Miyazaki et al., 2004; Yang et al.,
2005). In addition, we demonstrate the mechanisms
whereby BMP7 induces cancer cell death that involve the
repression of the hTERT gene and subsequent inhibition of
telomerase activity and shortening of telomeres. We show
that BMP7-induced cancer cell senescence and death are
signiﬁcantly reduced after hTERT gene is constitutively
overexpressed to prevent telomerase inhibition. Consis-
tently, silencing the hTERT gene induces breast cancer cell
death without potentiating the effect of BMP7 on cancer cell
death. In addition, an additive effect has been observed
between BMP7 and hTERT shRNA on cell senescence and
apoptosis, and that establishing telomerase activity by
expressing hTERT does not completely eradicate BMP7-
induced cell senescence and apoptosis. These data suggest
that other mechanism(s) than hTERT gene repression are
also involved in BMP7-induced breast cancer cell senes-
cence and apoptosis.
We note for the ﬁrst time that BMP7 exerts its inhibitory
effect by a mechanism involving Smad3 nuclear signaling.
BMP7 induces Smad3 phosphorylation, nuclear transloca-
tion and gene transcriptional activity in a time course
occurring within an hour. As a repressor the hTERT gene,
Smad3 expression induces telomerase inhibition (Li and Liu,
2007). When Smad3 is silenced, the repression of the
hTERT gene and inhibition of telomerase activity induced by
BMP7 is abolished. So, BMP7 stimulates the
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phosphorylation and nuclear accumulation of Smad3 in
addition to that of Smad1/5/8, and that Smad3 mediates
BMP7-induced telomerase inhibition, suggest that BMP7 is
coupled with Smad3 signaling in regulating telomerase
maintenance of telomere homeostasis. Our ﬁndings are
consistent with previous ﬁndings that BMP7 is shown to
induce phosphorylation of Smad2/3 in Barrett’s adenocarci-
noma cells (Rees et al., 2006) and that BMP7 stimulates
Smad3 target CAGA box promoter activity to a similar extent
to that induced by TGF-β in a mammary epithelial cell line
(Piek et al., 1999). In Barrett’s adenocarcinoma cells,
Smad2/3 is phosphorylated in the presence of BMP7 and
absence of TGF-β, but phosphorylation is inhibited with
increasing concentrations of TGF-β (Rees et al., 2006). This
TGF-β concentration-dependent inhibition of Smad2/3
phosphorylation may reﬂect complex cross-talks in signal
transductions between BMP7 and TGF-β.
Whereas further studies are required to investigate the
mechanism underlying the actions of BMP7 in stimulating
Smad3 signaling in this and previous work (Piek et al., 1999;
Rees et al., 2006) and inhibiting TGF-β-induced Smad3
signaling (Wang and Hirschberg, 2004b; Buijs et al., 2007a),
several possibilities may exist to explain the different differ-
ential signal transduction. First, different receptors stimulated
by BMP7, the potential presence of other cytokines, as well
as other intracellular signaling proteins might be account-
able under the speciﬁc conditions of different cell types. In an
attempt to investigate a potential role of Smad1/5/8 in reg-
ulating the hTERT gene, our preliminary data did not show
that Smad1/5/8 mediated BMP7 inhibition of telomerase
activity and telomere maintenance (unpublished). Given that
TGF-β induces a cross-talk of signaling to the Smad1/5/8
pathway in cancer and endothelial cells (Liu et al., 1998;
Goumans et al., 2002), it is possible that BMP7 coupling to
the Smad3 signaling pathway is involved in regulating gene
expression program beyond that of the hTERT directly or
indirectly via a gene transcription-dependent mechanism.
To investigate potential roles of the different type II
receptors of the TGF-β family in mediating a regulatory
program over the hTERT gene, we carried out dominant
negative gene expressions of all four TGF-β RII receptors.
Our ﬁndings that removal of the cytoplasmic domain of
BMPRII receptor, but not other TGF-β RII or activin RII
receptors, results in high hTERT gene promoter activity, high
telomerase activity and long telomeres, demonstrating that
BMPRII mediates an inhibitory signaling to the hTERT gene
promoter. The data provide evidence to suggest a possible
mechanism underpinning the relatively low levels of the
hTERT gene promoter activity due to an inhibitory regulation
mediated by BMPRII receptor in the breast cancer cells (Xu
et al., 2008). Further, our ﬁndings that BMPRII receptor
mutant blocks BMP7-induced repression of the hTERT gene
promoter in both MCF-7 and PMC42 breast cancer cells
demonstrate a BMP7- BMPRII receptor pathway in a nega-
tive regulation of the hTERT gene. Since ACTRIIB receptor
mutation also inhibits BMP7-induced repression of the
hTERT gene promoter albeit to less degree than that of
BMPRII receptor, we cannot exclude a possibility that
ACTRIIB receptor is also involved in mediating BMP7 neg-
ative regulation of telomerase activity which requires future
studies. In conclusion, we demonstrate that BMP7 exerts a
potent inhibitory effect on telomerase activity and telomere
maintenance in human breast cancer cells, causing cancer
cell ageing and death, via BMPRII receptor and Smad3
signaling to repression of the hTERT gene.
MATERIALS AND METHODS
Cytokines, RNAi, gene expression plasmids and antibodies
Bone Morphogenetic Protein (BMP) 2, 4, 5, 6, and 7 were from R&D
systems (Minneapolis, MN, USA). Smad3 siRNA and control siRNA
were from Ambion (Austin, TX, USA), c-myc and relevant control
siRNAs were from Cellogenetic. Plasmid pEGFP-C1, pEGFP-C1-
hTERT, and pEGFP-C1-hTERT small hairpin RNA (shRNA) were
produced in this laboratory. For the hTERT shRNA expression
construct, oligonucleotide (Table S1) was annealed and cloned to
the EcoR1 site downstream of the U6 promoter. All plasmids were
veriﬁed by DNA sequencing. For gene expressions, total RNA and
proteins were extracted and processed for Western blotting and RT-
PCR as described previously (Li et al., 2006; Xu et al., 2008). For
subcellular distribution of Smad3, cell fractionation and immunoﬂu-
orescence staining were conducted by differential centrifugations
and standard immunocytochemistry respectively, as described
elsewhere previously (Li et al., 2006; Xu et al., 2008). GFP or CFP
fusion proteins were monitored by ﬂuorescence microscopy and
further veriﬁed by confocal microscopy as described previously
(Yang et al., 2001). The primary antibodies of mouse anti-phospho-
Smad3, mouse anti-c-myc, mouse anti-p53, and mouse anti-p21
were from Santa Cruz Biotechnology, CA, USA. The primary anti-
bodies of rabbit anti-p16 were from Cell Signaling Technology, MA,
USA, mouse anti-actin from Chemicon, and horseradish peroxidise-
coupled second antibodies from Dako.
Generation of TGFβ family receptor R2 dominant negative mutants
The plasmid construct encoding the ﬁrst 172 amino acids of BMPRII
fused to EGFP was provided by Claude Labrie (Universite Laval,
Quebec, Canada). The sequences of BMPRII, ACTRIIA, ACTRIIB
and TGFβRII were aligned, and constructs encoding similarly trun-
cated proteins were produced as fusions to GFP or CFP as indicated
in individual experiments. PCR was performed using HeLa cell
cDNA for ACTRIIA 1-161, ACTRIIB 1-160 and TGFβRII 1-214 were
performed, and the PCR products were on-gel puriﬁed, digested
using EcoRI and BamHI (NEB) and cloned into the same sites in
pEGFP-N1.
Cell culture, treatment, transfection and sorting
Human breast cancer MCF-7 cell line was grown in 5% CO2 atmo-
sphere at 37°C in Dulbecco’s modiﬁed Eagle’s medium (Invitrogen)
containing 0.5% fetal bovine serum in 6-well plastic plates or 10-cm
dishes. Cells were treated with puriﬁed recombinant cytokines at
different concentrations added into culture medium in a one tenth
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volume for 1–4 days. Pulsatile chonic treatment was carried out by
incubating cultured cells with BMP7 for 15 h followed by replacing
with fresh medium and further cultures of two days. The treatment
was repeated in two days continuously for two weeks. Cell trans-
fection was conduced using Lipofectamine-2000 (Invitrogen)
according to the manufacturer’s instruction. After a 24-h transfection,
GFP transfected cells were sorted using FACSAria ﬂow cytometer
(BD Biosciences, San Jose, CA). The GFP positive cells were re-
seeded into 6-well plates at a density of 0.2 × 106 cells/mL in DMEM
plus 10% FBS including Gentamicin antibiotics (Pﬁzer, Australia).
Cells were treated with cytokines for different periods and analysed
in Western blotting and semi-quantitative RT-PCR analysis to detect
gene expressions as indicated in individual experiments. For sub-
cellular distribution between cytoplasm and nucleus, cell fractiona-
tion was performed by differential centrifugation.
Cell senescence and apoptosis analysis
β-Galactosidase staining was performed for cell senescence by
incubation cells with 2 mL of staining solution (1 mg/mL X-gal,
40 mmol/L citric acid/Na phosphate buffer, pH 6.0, 5 mmol/L potas-
sium ferrocyanide, 5 mmol/L potassium ferricyanide, 150 mmol/L
NaCl, and 150 mmol/L MgCl). The stained plates were wrapped with
paraﬁlm to protect against pH changes and incubated overnight at 37°
C. The cells were rinsed and stored in PBS, and analyzed by micro-
scopy (Nikon). Apoptotic cells were analyzed a FACSCalibur ﬂow
cytometer (BD Biosciences, San Jose, CA, USA), by incubating with
annexin-V-FLUOS conjugate (Roche Diagnostic, Australia) and pro-
pidium iodide (PI) (Sigma) for 15 min at room temperature. Samples
were then analyzed using FL-2 and FL-3 channel respectively. An
acquisition gate was set to include ∼20,000 of the centrally located
cells for each sample acquisition using linear forward scatter versus
linear side scatter. This acquisition strategy resulted in ∼40,000
ungated events being included for each sample analysis
Luciferase gene reporter assay
The p(CAGA)13 Luc TGF-β-inducible luciferase reporter construct
(0.5 µg) was transfected into cultured breast cancer cells to deter-
mine Smad3 signaling as described previously (Li et al., 2006).
Brieﬂy, cells were co-transfected with Renilla luciferase and control
reporter (pRL-TK) for 48 h. During the last 24 h of 48 h transfection,
cells were treated with different cytokines indicated in individual
experiments. Human TERT promoter activity was measured from
the recombinant hTERT promoter p330-Luc (Genebank ACCES-
SION AB018788) upstream of Renilla luciferase reporter gene.
Transfections were carried out using LipofectAMINE2000 (DNA:
LipofectAMINE2000 = 1:3) as described in the user manual. The
dual-luciferase assay was analysed using Wallac Victor Light plate
reader (Perkin-Elmer, United States of America).
Telomerase activity and telomere length analysis
Telomerase activity was determined by TRAP as described previ-
ously (Li et al., 1997). For telomeres in cultured cells, metaphase
spreads from cycling MCF-7 cells treated with or without BMP7
(30 ng/mL, 15 h) thee times per week for two weeks were generated
using standard laboratory protocols. The slides of metaphase cells
or tumor sections were ﬁxed in 4% formaldehyde before treatment
with acidiﬁed 1% pepsin solution, and hybridized with probe solution
(0.3 µg/mL Cy3-conjugated [CCCTAA]3 PNA probe (Panagene,
Daejeon, South Korea), 70% formamide, 20 mmol/L Tris-HCl, pH
7.0, 1% BSA). Washing was conducted in PBS/tween-20 with one
high stringency wash at 57°C. DNA was counterstained with DAPI
and visualized and captured using Nikon Eclipse TE2000 micro-
scope, Plan Fluor 40× objective, DS-5MC CCD camera and NIS-
Elements F 2.20 software (Nikon). Telomere images were captured
with a Plan Fluor 100× oil-emersion objective, and individual
telomere ﬂuorescence was integrated using spot IOD analysis in the
TFL-Telo 2.2 program (gift from Dr. Peter Lansdorp, Vancouver)
(Rufer et al., 1998). Images from at least 13 metaphase spreads
from each data point were quantiﬁed before assembly of data in a
standard spreadsheet program. At least 50 nuclei from each con-
dition were analyzed. Average length of telomere repeat fragment
(TRF) from mass cell cultures were determined by in-gel hybridiza-
tion following collection of total genomic DNA, HindF1/RSA1
digestions and pulse-ﬁeld agarose gel electrophoresis, using
radioisotope-labelled oligonucleotide probe (sequence in Table S1).
The mean TRF length was assessed using the formula TRF = Σ
(OD)/Σ (OD/L) as described elsewhere (Roche Diagnostic,
Australia).
Statistical analysis
Data were analysed using student t-tests for difference between two
means, and Kolmogorov-Smirnov test using GraphPad Prism for
difference between telomere ﬂuorescence distributions. A probability
(P) value of at least less than 0.05 was considered statistically
signiﬁcant.
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